New Trends in the Treatment of Neuropsychiatric Disorders
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: 30 April 2026 | Viewed by 20
Special Issue Editors
Interests: brain cancer; molecular mechanism; natural compounds
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Neuropsychiatric disorders are conditions that involve both neurological and psychiatric symptoms, affecting cognition, emotion, and behavior. Common examples include depression, schizophrenia, bipolar disorder, and Alzheimer's disease, often resulting from complex interactions between genetic, biological, and environmental factors. This Special Issue will explore cutting-edge advances in the treatment of neuropsychiatric disorders, highlighting emerging therapeutic strategies and innovative research. It will cover a broad range of topics, including novel pharmacological agents, neuromodulation techniques (such as transcranial magnetic stimulation and deep brain stimulation), and personalized medicine approaches informed by genetics and biomarkers. This Special Issue will also emphasize the role of digital therapeutics, AI-driven diagnostics, and integrative models that combine psychological, neurobiological, and social perspectives. Together, these contributions reflect a paradigm shift toward more targeted, effective, and individualized care for conditions such as depression, schizophrenia, bipolar disorder, and anxiety.
Dr. Terezia Kiskova
Dr. Aneta Bednarova
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- treatment
- depression
- schizophrenia
- bipolar disorder
- Alzheimer’s disease
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
